Bangkok Genomics Innovation PCL (BKK:BKGI) Equity-to-Asset : 0.82 (As of Mar. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Bangkok Genomics Innovation PCL Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Bangkok Genomics Innovation PCL's Total Stockholders Equity for the quarter that ended in Mar. 2023 was ฿243.30 Mil. Bangkok Genomics Innovation PCL's Total Assets for the quarter that ended in Mar. 2023 was ฿298.48 Mil. Therefore, Bangkok Genomics Innovation PCL's Equity to Asset Ratio for the quarter that ended in Mar. 2023 was 0.82.

The historical rank and industry rank for Bangkok Genomics Innovation PCL's Equity-to-Asset or its related term are showing as below:

BKK:BKGI' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.44 Med: 0.8 Max: 0.82
Current: 0.81

During the past 5 years, the highest Equity to Asset Ratio of Bangkok Genomics Innovation PCL was 0.82. The lowest was 0.44. And the median was 0.80.

BKK:BKGI's Equity-to-Asset is ranked better than
85.23% of 237 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.58 vs BKK:BKGI: 0.81

Bangkok Genomics Innovation PCL Equity-to-Asset Historical Data

The historical data trend for Bangkok Genomics Innovation PCL's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bangkok Genomics Innovation PCL Equity-to-Asset Chart

Bangkok Genomics Innovation PCL Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

0.44

0.45

0.80

0.82

0.81

Bangkok Genomics Innovation PCL Quarterly Data
	Dec20	Dec21	Mar22	Dec22	Mar23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial			0.80	-	0.82	0.82	0.81

Competitive Comparison of Bangkok Genomics Innovation PCL's Equity-to-Asset

For the Diagnostics & Research subindustry, Bangkok Genomics Innovation PCL's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bangkok Genomics Innovation PCL's Equity-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Bangkok Genomics Innovation PCL's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Bangkok Genomics Innovation PCL's Equity-to-Asset falls into.

Bangkok Genomics Innovation PCL Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Bangkok Genomics Innovation PCL's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	235.819	/	293.021
	=	0.80

Bangkok Genomics Innovation PCL's Equity to Asset Ratio for the quarter that ended in Mar. 2023 is calculated as

Equity to Asset (Q: Mar. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	243.301	/	298.477
	=	0.82

Bangkok Genomics Innovation PCL (BKK:BKGI) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Bangkok Genomics Innovation PCL Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Bangkok Genomics Innovation PCL's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Bangkok Genomics Innovation PCL (BKK:BKGI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Bangkok Genomics Innovation PCL (BKK:BKGI) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

3689 Rama 4 Road, Phra Khanong Subdistrict, Khlong Toei Subdistrict, Bangkok, THA, 10110

Website

https://www.bangkokgenomics.com

Bangkok Genomics Innovation PCL operate a laboratory and provide medical analysis services. Its services includes Screening for genetic abnormalities in reproductive health (Reproductive Health Testing Services),Infectious Disease Analysis Product Group (Infectious - Related Testing Services), Other screening product groups (Other Testing Services), providing technology services (Tech Solution Services), and Sales of other medical products Related (Medical - Related Products).